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Summary The effects of several members of the family of lamellarins, polyaromatic alkaloids isolated from
tunicates belonging to the genus Didemnwn, on the growth of several tumour cell lines and on P-glycoprotein
(P-gp)-mediated multidrug resistance (MDR), were investigated. Cytotoxicity experiments of lamellarins were
performed on a panel of tumour cell lines, including two multidrug-resistant cell lines. Some lamellarins showed
good anti-tumour activity, with similar levels of cytotoxicity against both the resistant and their corresponding
parental cell lines. Two lamellarins displayed a high potency against lung carcinoma cells. Studies of the
resistance modifier activity of the different lamellarins at non-toxic concentrations were also carried out in cells
exhibiting MDR, and lamellarin I was selected for the highest chemosensitising activity. At non-toxic doses,
verapamil and lamellarin I effectively increased the cytotoxicity ofdoxorubicin, vinblastine and daunorubicin in
a concentration-dependent manner in multidrug-resistant cells, but the potency of lamellarin I as a MDR
modulator was 9- to 16-fold higher than that of verapamil. In vitro measurements of rhodamine 123
accumulation in the multidrug-resistant Lo Vo/Dx cells suggest that lamellarin I reverses MDR by directly
inhibiting the P-gp-mediated drug efflux. This work underscores the possibility of using these marine-derived
compounds as a potential new source of anti-tumoral drugs active on resistant cells as well as of non-toxic
modulators of the MDR phenotype.
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Development of drug resistance is one of the major obstacles
to effective cancer chemotherapy. Clinical resistance to anti-
cancer agents occurs at the time of presentation as well as
during the course of treatment and at relapse.
Although a number of different drug resistance mechan-
isms has been identified in the laboratory, perhaps the most
intensively studied has been multidrug resistance (MDR),
which is characterised by a failure to respond to a variety of
chemotherapeutic agents that do not share a common
structure or a common intracellular target. It is now well
established that the major mechanism of MDR in
mammalian cells involves the overexpression of a 170 kDa
plasma membrane glycoprotein (P-gp), encoded in humans
by the gene MDRJ. P-gp belongs to the ATP-binding cassette
superfamily of transporter proteins, and is thought to
function as a broad-substrate ATP-dependent pump, which
exports drugs out of mammalian cells, lowering the
intracellular drug concentration below the cytotoxic thresh-
old (For recent reviews see Gottesman and Pastan, 1993;
Patel and Rothenberg, 1994).
Many studies have attempted to assess the contribution of
P-gp to clinical outcome. Overexpression of the MDR] gene
has been found in tumours derived from tissues that normally
express this gene, as well as in untreated cancers derived from
tissues that do not express MDRI at detectable levels (Nooter
and Herweijer, 1991). In some cases, correlations have been
made between expression of P-gp and poor prognosis, which
included failure to respond to chemotherapy. Increased
expression of MDR] is often seen in tumours treated with
chemotherapy that have relapsed during the course of, or
after chemotherapy (Arceci, 1993). Moreover, it has recently
been suggested that the process of malignant transformation
per se can activate the expression of the MDRI gene
(Benchimol and Ling, 1994).
A goal of current cancer research is to find ways to
overcome or circumvent drug resistance due to expression of
P-gp. Attempts to overcome the problem of MDR involve
two main approaches: the first one includes the search for
clinically useful drugs that retain relatively good activity on
multidrug-resistant cells. The second major approach to the
circumvention of MDR is the use of resistance modifiers, that
is, agents that are able to reduce the degree ofdrug resistance
in multidrug-resistant cells by interfering with the pump's
drug efflux function. These drugs, also referred to as MDR
reversal agents, inhibit the efflux of P-gp substrate drugs out
of cells in vitro, and result in the 'resensitisation' of the
resistant malignant cell.
Since the early observation of Tsuruo et al. (1981) that
non-cytotoxic doses of verapamil could restore sensitivity to
vinca alkaloids in multidrug-resistant cells, a large number of
resistance modifier agents (RMAs) has been found, including
calcium-channel blockers (Tsuruo et al., 1983), calmodulin
inhibitors (Ganapathi and Grabowski, 1983), tamoxifen and
its analogues (Ramu et al., 1984), cyclosporins (Twentyman,
1988) and protein kinase inhibitors (Miyamoto et al., 1993).
These agents were originally developed for pharmacological
effects other than circumvention of MDR, and therefore dose
escalation in MDR reversal studies has often resulted in
serious toxicities. Existing problems associated with their use
as RMAs include the inability to achieve clinically effective
plasma concentrations sufficient to inhibit P-gp activity, their
short half-life and rapid clearance, and the unacceptable
toxicities of these drugs when used at levels effective in
sensitising cancer cells (Ozols et al., 1987; Miller et al., 1988;
Pennock et al., 1991). Although several agents that are much
more effective at sensitising multidrug-resistant cells in vitro
than compounds previously examined as modulators have
been described, such as the non-immunosuppressive cyclos-
porin A analogue PSC-833 (Twentyman and Bleehen, 1991)
and the cyclopeptolide SDZ 280-446 (Loor et al., 1992), no
definitive MDR inhibitor is yet available in the clinic. More
efforts have to be devoted to the development of more
specific inhibitors of P-gp that lack undesired side-effects that
could make their clinical use difficult, and to the development
of drugs active on cells showing the MDR phenotype.
Lamellarins are polyaromatic alkaloids previously isolated
from Lamellaria sp., a prosobranch mollusc collected in
Palau island (Andersen et al., 1985) and from tunicates
belonging to the genus Didemnum, Didemnum chartaceum
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from the Seychelles island (Lindquist et al., 1988) and
Didemnum sp. from the Great Barrier Reef (Carroll et al.,
1993). Most probably the reason for the presence of these
compounds in the mollusc is the use of these ascidians as a
food source. This paper describes the cytotoxic activity of
some lamellarins on multidrug-resistant cells, as well as their
activity as resistance modifiers. This reversing effect has been
compared with that of verapamil, which is considered to be
the reference compound. Our results suggest the importance
ofusing marine-derived compounds as a potential new source
of modulators of the MDR phenotype.
Materials and methods
Chemicals
Doxorubicin, daunorubicin, vinblastine and verapamil were
purchased from Sigma Chemicals (St Louis, MO, USA).
Rhodamine 123 was from Molecular Probes (Eugene, OR,
USA). Lamellarins, isolated from Didemnum sp. (Carroll et
al., 1993), were kindly provided by Dr B Bowden of James
Cook University, North Queensland, Australia. Their
structures are shown in Figure 1. Cell culture reagents and
media were from Gibco (Paisley, UK), and fetal calf serum
(FCS) was purchased from Seromed-Biochrom (Berlin,
Germany).
Cell lines and culture
Parental murine leukaemia P388 cells and multidrug-resistant
P388/Shabel cells (showing a relative resistance to doxo-
rubicin of about 100-fold and to daunorubicin and
vinblastine of about 200-fold in comparison with its parental
cell line) and parental human colon adenocarcinoma LoVo
and multidrug-resistant Lo Vo/Dx cells (showing a relative
resistance to doxorubicin of about 30-fold in comparison
with its parental cell line) were kindly supplied by Dr M
Grandi (Pharmacia-Farmitalia, Nerviano, Italy). Both
resistant cell lines were selected by growth in the presence
of doxorubicin for the multidrug-resistant phenotype (Grandi
et al., 1986, 1987). P388/Schabel cells exhibit a high level of
MDR] gene expression; no evidence of gene amplification has
been found in our laboratory (unpublished data). MDR]
mRNA is overexpressed in Lo Vo/Dx cells (Conforti et al.,
1995). Collateral sensitivity phenomenom is not exhibited by
P388/Schabel cells, whereas Lo Vo/Dx cells are collaterally
sensitive to verapamil (Quesada et al., 1996). P388 and P388/
Schabel were routinely maintained (37°C, 5% carbon dioxide
in a humid atmosphere) in RPMI-1640 medium, supplemen-
ted with 2 mM L-glutamine, 20 ,UM fl-mercaptoethanol,
100 IU ml-1 streptomycin-penicillin and 10% FCS. Lo Vo
and Lo Vo/Dx cells were cultured in HAM'S F12 medium,
supplemented with 2 mM L-glutamine, 1% vitamin mixture,
100 IU ml-' streptomycin-penicillin and 10% FCS. The
media for P388/Schabel and Lo Vo/Dx cells were further
supplemented with 200 ng ml-1 and 100 ng ml-1 doxorubicin
respectively, in order to keep their MDR phenotype stable.
One day before experimental use the culture medium of the
multidrug-resistant cell lines was removed, and the cells were
grown in drug-free medium.
The AUXB1 cell line, which is auxotrophic for glycine,
adenosine and thymidine (Thomson and Baker, 1973;
McBurney and Whitmore, 1974) is the wild-type CHO
(chinese hamster ovary) line from which CCHRC5 (showing
a relative resistance to doxorubicin of 25-fold in comparison
with its parental cell line) was selected by Ling et al. (Ling,
1982; Kartner et al., 1985). Both CHO cell lines were kindly
provided by Dr RC Hughes Jr. (Roswell Park Cancer
Institute, Buffalo, NY, USA) and were maintained (37°C,
5% carbon dioxide in a humid atmosphere) in logarithmic
phase of growth in Eagle's minimum essential medium with
Earle's balanced salts, 0.01 M sodium bicarbonate, 1% non-
Figure 1 Chemical structure of the lamellarins tested.
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essential amino acid mixture, 2 mM L-glutamine, 100 IU ml-'
streptomycin-penicillin (EMEM/neaa), supplemented with
10 mg ml-' adenine, 10 mg ml- 1 thymidine and 5% FCS.
A549 (ATCC, CCL185) human lung carcinoma, HT29
(ATCC, HTB38) human colon carcinoma and MEL28
(ATCC, HTB72) human melanoma cells were purchased
from the American Type Culture Collection (Rockville, MD,
USA) and maintained in EMEM/neaa medium supplemented
with 5% FCS.
Cytotoxicity assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT; Sigma Chemical Co., St Louis, MO, USA) dye
reduction assay in 96-well microplates was used, essentially as
described (Mosmann, 1983). The assay is dependent on the
reduction of MTT by mitochondrial dehydrogenase of viable
cell to a blue formazan product that can be measured
spectrophotometrically. Cells (103 in a total volume of 100 Pl
of culture medium) were incubated in each well with serial
dilutions of the compound to be assayed for its cytotoxicity.
After 3 days of incubation (37°C, 5% carbon dioxide in a
humid atmosphere) 10 Ml of MTT [5.0 mg ml-' in phosphate
buffered saline (PBS)] were added to each well and the plate
was incubated for a further 4 h (370C). The resulting
formazan was dissolved in 150 ,ul of 0.04 N HCl-2-propanol
and read at 570 nm. All determinations were carried out in
triplicate. IC50 value was calculated as the concentration of
antitumoral drug yielding 50% of cell survival.
Chemosensitisation assay
For the chemosensitisation assay a complete antitumoral
drug dose-cell growth response curve was constructed as
indicated above at each RMA concentration. A whole range
of IC50+ values were thus obtained in the presence of the
different RMA concentrations, the IC50- being obtained in
the absence of RMA. The increase of sensitivity to the
antitumoral drug was expressed as 'gain of sensitivity' (Keller
et al., 1992), and calculated for each RMA concentration
from the ratio IC,0-/IC50 +.
Rhodamine 123 accumulation measurement
Rhodamine 123 accumulation was measured with a
microplate-adapted assay, as previously described (Quesada
et al., 1996). Lo Vo or Lo Vo/Dx cells (105 cells per well)
were preincubated (37°C, 5% carbon dioxide) 4 h in 96-well
microplates with the indicated RMA concentration before the
addition of 20 ,uM rhodamine 123. After an additional 30 min
incubation at 37°C, cells were washed three times with ice-
cold PBS, and rhodamine 123 accumulation was measured
with a fluorescence microplate reader (k excitation=485 nm,
X emission = 530 nm).
Results
Antitumoral activity of lamellarins
Structures of the different lamellarins studied are shown in
Figure 1. The cytotoxicities of these compounds on several
tumour cell lines, including two multidrug-resistant cell lines
were tested. As shown in Table I, all lamellarins displayed
some cytotoxicity on the tumour cells. Lamellarins D-
triacetate, K, K-triacetate, M and N-triacetate turned out
to be those with the highest cytotoxic activity on all the cell
lines tested. The level of activity of the mentioned lamellarins
on the multidrug-resistant cells is similar to that obtained on
their respective parental cell lines. It should also be pointed
out the high cytotoxicity of lamellarins D-triacetate and K-
triacetate against A549 lung carcinoma cells.
Reversal of doxorubicin, daunorubicin and vinblastine
resistance by lamellarins
Initially, the lamellarins isolated during our screening
programme were tested at concentrations of 10 and
1 jug ml-1 with the above-described microplate assay, based
on the measurement of the increase of rhodamine 123
accumulation in multidrug-resistant Lo Vo/Dx cells, caused
by the presence of a RMA (results not shown). This assay
allows the compound to be tested at toxic concentrations as
incubation times are not sufficient to detect cell death. From
this primary screening, lamellarin I was chosen to be further
tested for its ability to restore doxorubicin toxicity in
multidrug-resistant P388/Schabel. The human colon carcino-
ma cell line Lo Vo/Dx was not used for the sensitisation
studies because it displays the collateral sensitivity phenom-
enon (Biedler, 1994). Sensitivity of Lo Vo/Dx cells to
verapamil exhibits a multiphasic curve that indicates that
only a small population of cells is able to survive at specific
low concentrations of verapamil. An additional problem may
come from the fact that this is not a general phenomenom for
all RMAs as, when another chemosensitiser such as PSC833
is used, no collateral sensitivity of Lo Vo/Dx is observed
(Quesada et al., 1996). Caution should be taken when using a
cell line that exhibits collateral sensitivity in chemosensitisa-
tion assays because an increase in toxicity to the antitumoral
drug (e.g. doxorubicin) might not be due to inhibition of P-
gp, but to a selective toxicity of the compound to the
resistant cells. Therefore, for chemosensitisation studies it is
advisable to use cell lines that do not exhibit this
phenomenom such as P388/Schabel cells (Quesada et al.,
1996).
Table I Cytotoxic activity of different lamellarins against a panel of tumour cell lines
Mean IC,O (tuM)
Lamellarin P388 Schabel AUXBI CCH`C5 A549 HT29 MEL28
A 0.89 (0.10) 0.91 (0.08) 0.36 (0.07) 0.71 (0.12) 0.90 (0.13) 2.1 (0.4) 0.93 (0.10)
B 10.1 (1.3) 10.4 (0.9) 5.5 (0.7) 18.0 (2.4) 5.2 (0.9) >10 10.1 (0.2)
D-tac 0.11 (0.03) 0.14 (0.02) 0.05 (0.01) 0.06 (0.01) 0.008 (0.001) 0.80 (0.11) 0.16 (0.02)
I 4.9 (0.5) 4.8 (0.7) 0.38 (0.05) 2.0 (0.2) 5.0 (0.8) 4.7 (0.5) 5.0 (0.3)
I-acetate 9.0 (1.2) 9.2 (0.8) 4.1 (0.5) 9.0 (1.0) 9.3 (1.3) >10 9.1 (1.2)
J 2.9 (0.4) 3.9 (0.5) 0.58 (0.04) 1.2 (0.2) 0.60 (0.06) 5.8 (0.7) 2.9 (0.4)
K 0.19 (0.01) 0.017 (0.02) 0.19 (0.02) 0.75 (0.10) 0.18 (0.03) 0.38 (0.03) 0.40 (0.05)
K-tac 0.09 (0.01) 0.16 (0.02) 0.15 (0.01) 0.16 (0.03) 0.005 (0) 0.47 (0.06) 0.93 (0.12)
L 1.2 (0.1) 1.4 (0.2) 0.80 (0.09) 1.3 (0.1) 0.60 (0.04) 6.0 (0.8) 1.2 (0.2)
L-tac 2.4 (0.3) 2.4 (0.1) 2.2 (0.2) 2.5 (0.3) 1.1 (0.1) >3 2.3 (0.2)
M 0.15 (0.03) 0.17 (0.02) 0.07 (0.01) 0.17 (0.01) 0.06 (0.01) 0.56 (0.07) 0.54 (0.04)
M-tac 0.91 (0.11) 1.1 (0.2) 0.76 (0.09) 3.1 (0.5) 0.22 (0.05) >1 0.90 (0.13)
N-tac 0.32 (0.02) 0.30 (0.04) 0.10 (0.03) 0.16 (0.02) 0.02 (0) 3.2 (0.02) 1.6 (0.03)
Fifty per cent inhibitory concentration (IC50) represents the mean (standard deviation in parentheses) from dose- response curves of 2 - 3
experiments. tac, triacetate.
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Chemosensitisation assays measure the consequences of
inhibiting P-gp function on cell growth. They require RMA
concentrations that are not inhibitory or toxic per se. In the
present study, only RMA concentrations yielding less than
10% growth inhibition of P388/Schabel cells when tested in
the absence of doxorubicin or any other drug were
considered. Figure 2 shows the effect of lamellarin I and
verapamil at different concentrations on the cytotoxicity of
doxorubicin on multidrug-resistant cells. As shown in this
figure, P388/Schabel cells were fairly resistant to doxorubicin,
but were sensitised to the levels of the parental cells when co-
incubated with lamellarin I. The sensitising effect was
observed at concentrations as low as 0.2 pM and full
potentiation is observed at 2 gM, in which the doxorubicin
dose-dependent curve resembled that of the sensitive cell line
(P388). In contrast, the full potentiating effect of the
prototype MDR inhibitor (verapamil) was observed only in
the supramicromolar range (at 20 gM). Chemosensitisation
was also observed when other cross-resistant drugs such as
daunorubicin and vinblastine were used. The potentiating
effect of lamellarin I on doxorubicin, daunorubicin and
vinblastine toxicities is summarised in Table II. As shown in
Table II, a complete reversion of doxorubicin, daunorubicin
and vinblastine resistance (i.e. the gain of sensitivity equal to
the relative resistance between the parental and the multi-
drug-resistant cell line; for calculation of gain of sensitivity,
see Materials and methods), could be obtained with 2 gM
lamellarin I, which is within the range of RMA dosages that
do not per se cause a substantial inhibition of cell growth.
100
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Figure 2 Dose-dependent effect on the in vitro growth of
multidrug-resistant P388/Schabel cells by doxorubicin alone (-
O-) or in the presence of 20 (-0-) or 2 gM (-O-) verapamil or 2 (-
A-) or 0.2 (---) gM lamellarin I. As a reference the growth of
P388 parental cells is displayed (-N-). Cell proliferation is
represented as percentage of control cell growth in cultures
containing no drugs. Each point represents the mean of
triplicates; s.d. values were always lower than 10% and are
omitted for clarity.
Ten-fold higher concentrations of verapamil were required to
obtain similar gains for chemosensitisation to doxorubicin
and vinblastine, whereas a complete reversion of the
resistance to daunorubicin could not be reached with non-
toxic concentrations of verapamil. If we use the MI (fold
decrease in resistance/modulator gM concentration) to
represent the effectiveness of an RMA as proposed by Beck
and Qian (1992), at 2 gM lamellarin I has MI values of 53, 99
and 105 for doxorubicin, daunorubicin and vinblastine
respectively. These values are 9- to 16-fold higher than
those obtained with 2 gM verapamil (6, 6.2 and 8.2 for
doxorubicin, daunorubicin and vinblastine respectively).
Effect of lamellarins on rhodamine 123 accumulation in
multidrug resistant-cells
Figure 3 shows the effects of increasing concentrations of
verapamil or lamellarin I on the intracellular accumulation of
rhodamine 123 in Lo Vo and P-gp-positive Lo Vo/Dx cells
after 30 min incubation with 20 pM rhodamine 123.
Compounds at toxic concentrations could be tested in
accumulation studies because incubation time is not
sufficient for cell death to occur. As shown in Figure 3,
rhodamine 123 accumulates in parental Lo Vo cells, but not
in multidrug-resistant Lo Vo/Dx cells. Verapamil and
lamellarin I increased the intracellular concentration of
rhodamine 123 in Lo Vo/Dx cells in a dose-dependent
manner, and raised it to the level observed in the sensitive
cells. At identical concentration, lamellarin I increased
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Figure 3 Effect of verapamil (0) and lamellarin I (-) on the
accumulation of rhodamine 123 by multidrug-resistant Lo Vo/Dx
cells in co-treatment conditions. Approximately 105 cells per well
were used in the assay. Rhodamine 123 accumulation in Lo Vo
parental cells is shown by a dashed line. Each point represents the
mean of four determinations+s.d.
Table II Gains of sensitivity (GS) to doxorubicin, daunorubicin and vinblastine for multidrug-resistant P388/Schabel cells, obtained with
different concentrations of verapamil and lamellarin I
Mean GS+s.d.a at 1M RMA
Antitumoral drug RMA 0.2 1 2 20
Doxorubicin Verapamil 1.0±0.4 4.1 +0.7 12.1 +4.6 101 + 17
Lamellarin I 2.7+0.5 46.8+ 8.1 105 11 *
Daunorubicin Verapamil ND 5.6+0.78 12.4+ 1.7 94.5+21
Lamellarin I ND 49+5.3 198+27 *
Vinblastine Verapamil ND 3.2+0.5 16.5 ±3.9 220+ 31
Lamellarin I ND 63+7.1 210+25 *
a Mean of 3 - 8 determinations in triplicate
+ s.d. ND, not determined; RMA, resistance modifier agent. *>50% growth inhibition by RMA
alone. For calculation of GS see Materials and methods.Cytotoxic and MDR-modudatn activities of amaIn
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steady-state rhodamine 123 accumulation to a higher level
than verapamil. The maximal enhancement in accumulation
in resistant cells was obtained using 40 and 10 pJm of
verapamil and lamellarin I respectively, and corresponds to
the level of rhodamine 123 measured in Lo Vo cells. Neither
of the agents modulated rhodamine 123 accumulation in the
sensitive cells.
Discussion
MDR remains a main obstacle to long-term successful cancer
chemotherapy. The clinical need to overcome this resistance
has fuelled the search for new cytotoxic drugs active on
MDR cells, as well as of compounds capable of blocking in
vio the activity of P-gp. Thus far, reversal of MDR by a
broad spectrum of compounds such as calcium channel
blockers, calmodulin inhibitors, local anaesthetics and
synthetic isoprenoids. has been described. However, in vivo
studies have been disappointing because MDR modulators
often reveal intolerably high toxic side-effects in humans and
on the other hand clinically relevant concentrations of MDR
modifiers can only rarely be achieved (Raderer and
Sheithauer, 1993).
The results of this study suggest that lamellarins may be
useful in the treatment of multidrug-resistant tumours by
means of two independent mechanisms of action: cytotoxicity
against cancer cells and enhancement of the cytotoxicity of
doxorubicin against MDR cells. restoring in them the levels
of sensitivity to those of the parental cells.
Five of the lamellarins tested: lamellarins D-triacetate, K,
K-triacetate, M and N-triacetate display considerable
cytotoxic activity against all the tumour cell lines tested.
Two of them, lamellarins D-triacetate and K-triacetate.
exhibit a higher activity on A549 human lung carcinoma
cells. The anti-tumour activity of the five lamellarins
mentioned on multidrug-resistant cell lines is similar to that
obtained on the corresponding parental cell lines. The mode
of action of the cytotoxicity of lamellarin alkaloids is still
unknown, but it seems obvious that their level of activity is
not affected by P-gp. This could be due to two different
reasons: either lamellarins are not extruded by P-gp, or they
inhibit P-gp pumping activity,. therefore allowing an effective
intracellular concentration of lamellarins in multidrug-
resistant cells. Our findings that all the lamellarins tested
are able to increase the intracellular accumulation of
rhodamine 123 in multidrug-resistant cells (results not
shown) support the last speculation.
Although a clear correlation between structure and
cytotoxic activity of the lamellarins tested cannot be
established, it seems that an increase in the number of
methylations and or methoxylations cause a decrease in the
antitumoral activity of the compounds. This is in agreement
with data from Toffoli et al. (1995). who have recently
reported that the presence of methoxy groups in the
verapamil molecule structure prevented cytotoxicity when
the verapamil analogues were used alone on a human colon
cell line.
After determination of cytotoxicity. the different lamellar-
ins were tested for chemosensitisation at non-toxic concen-
trations. In the primary screening, lamellarin I was the most
potent of all the lamellarins tested for both chemosensitisa-
tion to doxorubicin-mediated inhibition of P388 Schabel cell
growth. and restoration of the retention of rhodamine 123 in
Lo Vo Dx cells.
Lamellarin I completely reverses doxorubicin. daunorubi-
cin and vinblastine resistance in P388 Schabel cells at 2 pm.
Verapamil can completely reverse doxorubicin and vinblas-
tine resistance. but not daunorubicin resistance. at non-toxic
concentrations. The different pattern ofchemosensitisation by
verapamil and lamellarin I for doxorubicin. daunorubicin and
Vinblastine could be due to the existence of different drug
binding-transport sites on P-gp for different drugs or groups
ofdrugs. as previously suggested by Jachez et al. (1993b). and
it could suggest that verapamil and lamellarin I possess
different efficiencies at inhibiting those sites. Such preferences
have been described previously for a series of derivatives of
the natural macrolide antibiotic FK-506 (Jachez et al..
1993a).
Reduced intracellular drug accumulation. expression of P-
gp and reversibility by several classes of membrane-active
agents that increase the intracellular drug accumulation
characterise the MDR phenotype. Rhodamine 123 has
proved to be a helpful tool for the evaluation of the
activities of various molecules known or supposed to be
RMAs (Pourtier-Manzanedo et al.. 1993). Rhodamine 123.
which selectively locates in mitochondnra. is effluxed more
efficiently by MDR cells. and this efflux can be inhibited by
verapamil and other RMAs (Twentyman et al.. 1994).
Lamellarin I is able to increase rhodamine 123 retention in
the MDR Lo Vo Dx cells to a level similar to that of the
drug-sensitive Lo Vo cell line. This effect was obtained at a
lower concentration than that needed when the reference
substance. verapamil. is employed. Measurement of rhoda-
mine 123 accumulation yields a direct measurement of the
inhibition of P-gp function. The increase in accumulation of
rhodamine 123 in multidrug-resistant cells after addition of
lamellarin, supports the hypothesis that this compound
causes a modulation of resistance by inhibiting the pump
function of P-gp.
Although it is difficult to find structural features that are
common to a large number of chemosensitisers. it has been
suggested that RMAs are hydrophobic. contain two or more
planar aromatic rings. and a tertiary nitrogen (Zamora et al..
1988; Pearce et al., 1989). The structure oflamellarins fits this
proffle.
In conclusion, the potential use of lamellarins for the
treatment of multidrug-resistant tumours may follow two
different approaches: at toxic concentrations they can be used
as antitumoral drugs active on the resistant tumours. and at
non-toxic concentrations they can be employed as reversing
agents. that is. compounds able to potentiate the cytotoxic
activity of other antitumoral drugs such as doxorubicin.
The testing of additional lamellarins may disclose the
existence of other agents with either a higher cvtotoxic
activity on tumour cells. or a more potent modulating activity
on multidrug-resistant cells and low. if any. cytotoxic activity.
which could make their use preferable in future clinical trials.
Further in vitro as well as in vivo experiments will indicate
whether lamellarins can be of important clinical use as
antitumoral drugs and or in reversing multidrug resistance.
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